Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux CW, et al. New England Journal of Medicine. 2026. PMID 42253238 · DOI 10.1056/NEJMoa2600751.
FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration. Content current through May 31, 2026.
TRIUMPH-1 sponsor-reported topline results
Eli Lilly and Company. May 21, 2026. Sponsor news release; not a full peer-reviewed report.
TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results
Eli Lilly and Company. July 23, 2026. Sponsor news release; detailed publication pending.
PubChem Compound Summary for CID 950107: 5-Amino-1-methylquinolinium
National Center for Biotechnology Information. PubChem CID 950107; record modified July 25, 2026.
REIMAGINE 2 cagrilintide-semaglutide comparative phase 3 study
2026 comparative trial; PMID 42251859.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
MOUNJARO (tirzepatide) current prescribing information
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
FDA Evaluation of AOD-9604-Related Bulk Drug Substances
U.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee briefing document.
AICAR prevents and reverses diabetic polyneuropathy by regulating mitophagy
Experimental study. 2024. PMID 39795939.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
Once-weekly cagrilintide for weight management in people with overweight and obesity
Lau DCW, et al. The Lancet. 2021;398:2160–2172. PMID 34798060 · DOI 10.1016/S0140-6736(21)01751-7
AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects
Višnjić D, et al. Cells. 2021. PMID 34064363.
Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies
Awosemo O, et al. Journal of Pharmaceutical and Biomedical Analysis. 2021;204:114255. PMID 34304009 · DOI 10.1016/j.jpba.2021.114255
Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle
Neelakantan H, et al. Biochemical Pharmacology. 2019. PMID 30753815 · DOI 10.1016/j.bcp.2019.02.008
L-Carnitine Supplementation in Recovery after Exercise
Fielding R, et al. Nutrients. 2018. PMID 29534031.
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Neelakantan H, et al. Biochemical Pharmacology. 2018;147:141–152. PMID 29155147 · DOI 10.1016/j.bcp.2017.11.007
Small-molecule inhibitors of nicotinamide N-methyltransferase
J. Med. Chem. 2017. PMID 28548833 · DOI 10.1021/acs.jmedchem.7b00389.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis
Lee C, et al. Cell Metabolism. 2015. PMID 25738453.
Comparative study of nanoparticle-targeted therapeutics and bioconjugates
Daquinag AC, et al. Molecular Pharmaceutics. 2013. PMID 23871959.
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Barnhart KF, et al. Science Translational Medicine. 2011. PMID 22072637.
AOD-9604 development review
Wilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
Certain Bulk Drug Substances That May Present Significant Safety Risks
U.S. FDA. Current compounding safety-information page.
ZEPBOUND (tirzepatide) prescribing information
U.S. Food and Drug Administration. Current Drugs@FDA label for NDA 217806.
SYNCHRONIZE-1 trial registry
ClinicalTrials.gov NCT06066515.
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records